Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil Tablets USP, 20 mg (USRLD: Adcirca Tablets, 20 mg).

Tadalafil relaxes muscles of the blood vessels and increases blood flow to particular areas of the body. It is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).